Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Comparative Study

Clinical Trial, Phase II

Clinical Trial

Research Support, N.I.H., Extramural

Multicenter Study

Clinical Trial, Phase III

Meta-Analysis

Systematic Review

Case Reports

Clinical Trial, Phase I

Publication Year

From

Quick links

Individual year

2026

2025

2024

2022

2021

2020

2019

2018

2017

2016

2015

2014

2012

2011

2009

2008

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Phosphodiesterase 4 Inhibitors""[mesh_terms]

34 Results

Searching titles within these results

Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.

Adilia Rafael, Tiago Torres

European journal of dermatology : EJD 2016;26(1):3-8

Full Text

Abstract

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.

Hira Ghani, Babar Rao, Alicia Podwojniak, Isabella J Tan, Aarushi K Parikh, Bianca Sanabria

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2024;30(9):e70041

Free Full Text

Abstract

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies.

Deepa S Mandlik, Satish K Mandlik

Immunopharmacology and immunotoxicology 2021;43(2):105-125

Full Text

Abstract

Preterm Birth, Inflammation and Infection: New Alternative Strategies for their Prevention.

Víctor M Muñoz-Pérez, Mario I Ortiz, Raquel Cariño-Cortés, Eduardo Fernández-Martínez, Leticia Rocha-Zavaleta, Mirandeli Bautista-Ávila

Current pharmaceutical biotechnology 2019;20(5):354-365

Full Text

Abstract

An update on topical therapies for psoriasis.

Emily K Pender, Brian Kirby

Current opinion in rheumatology 2024;36(4):289-294

Full Text

Abstract

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.

Qin Kang, Jing-Si Chen, Huan Yang

Frontiers in immunology 2022;13():1021537

Free Full Text

Abstract

Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate-to-Severe Acne.

Nello Tommasino, Maria Carmela Annunziata, Luca Potestio, Maddalena Napolitano

Journal of cosmetic dermatology 2026;25(4):e70812

Full Text

Abstract

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Gezim Lahu, Andreas Huennemeyer, Oliver von Richter, Robert Hermann, Rolf Herzog, Nigel McCracken, Karl Zech

Journal of clinical pharmacology 2008;48(11):1339-49

Full Text

Abstract

Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding.

Yanaika Shari Sabogal Piñeros, Tamara Dekker, Barbara Smids, Christof J Majoor, Lara Ravanetti, Gino Villetti, Maurizio Civelli, Fabrizio Facchinetti, René Lutter

Pharmacology research & perspectives 2021;8(3):e00557

Free Full Text

Abstract

Pathogenesis of psoriasis and development of treatment.

Akane Minagawa, Ryuhei Okuyama, Eisaku Ogawa, Yuki Sato

The Journal of dermatology 2018;45(3):264-272

Full Text

Abstract

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

Nassr Nassr, Gezim Lahu, Christian de Mey

BMC clinical pharmacology 2011;11():7

Free Full Text

Abstract

Successful treatment of Darier's disease with apremilast and review of reported cases.

Yusuke Muto, Kengo Kinjyo, Yoshihide Asano

The Journal of dermatology 2025;52(1):138-141

Full Text

Abstract

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

A Buenestado, S Grassin-Delyle, F Guitard, E Naline, C Faisy, D Israël-Biet, E Sage, J F Bellamy, H Tenor, P Devillier

British journal of pharmacology 2012;165(6):1877-1890

Free Full Text

Abstract

Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.

E D Bateman, J Bousquet, M Aubier, D Bredenbröker, P M O'Byrne

Pulmonary pharmacology & therapeutics 2016;35 Suppl():S11-9

Full Text

Abstract

Evaluation of PDE4 inhibition for COPD.

Desuo Wang, Xiangli Cui

International journal of chronic obstructive pulmonary disease 2008;1(4):373-9

Free Full Text

Abstract

Results: 1 – 15 / 34

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Phosphodiesterase 4 Inhibitors""[mesh_terms]

Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies.

Preterm Birth, Inflammation and Infection: New Alternative Strategies for their Prevention.

An update on topical therapies for psoriasis.

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.

Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate-to-Severe Acne.

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding.

Pathogenesis of psoriasis and development of treatment.

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

Successful treatment of Darier's disease with apremilast and review of reported cases.

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.

Evaluation of PDE4 inhibition for COPD.

Results for
""Phosphodiesterase 4 Inhibitors""[mesh_terms]